These data suggest the local synthesis of a 30 kDa endostatin-related fragment following acute renal failure and suggest its role in the modulation of renal capillary density.
Renal cell carcinoma (RCC) accounts for approximately 3% of new cancer incidence and mortality in the United States. Unfortunately many RCC masses remain asymptomatic and nonpalpable until they are advanced. Diagnosis and localization of early carcinoma play an important role in the prevention and curative treatment of RCC. The autofluorescence of blood porphyrin of healthy and tumor induced in male SCID mice was analyzed using fluorescence and excitation spectroscopy. A significant contrast between normal and tumor blood could be established. Blood porphyrin fluorophore showed enhanced fluorescence band (around 630 nm) in function of the tumor growth. This indicates that either the autofluorescence intensity of the blood fluorescence may provide a good parameter for the "first approximation" characterization of the tumor stage.
We investigated whether transfer of the gene encoding the angiogenesis inhibitor endostatin into the NIH/3T3 fibroblast cell line could inhibit renal tumor growth in vivo. NIH/3T3 cells were transduced with retroviral vectors containing the murine endostatin (ES) gene. SCID mice bearing CaKi-1 derived tumors were given a subcutaneous injection of either ES-transduced cells or control cells and were monitored for tumor growth. At the end of the in vivo experiment, the mean tumor volume of treated mice was 51.6 +/- 2.4 mm3, while the tumor volume of control was 234.5 +/- 14.8 mm3. Microvascular density was significantly decreased on treatment (control 9.79 vs. ES 2.53%, <0.001) accompanied by a 23-fold increase in intratumoral necrotic area and a 2.94-fold increase in the apoptotic index, determined by immunohistochemistry with anti-activated caspase-3. Apoptotic cells were found in foci enriched in infiltrating leukocytes. In conclusion, retroviral endostatin gene transfer led to secretion of functional endostatin that was sufficiently active to inhibit tumor angiogenesis and tumor growth. A second mechanism may also be implied in endostatin-dependent tumor regression, associated with tumor infiltration of leukocytes. Besides its antiangiogenic properties, endostatin may be a promising adjuvant to immunotherapy.
BackgroundStudies have shown the impact of atrial fibrillation (AF) on the patients'
quality of life. Specific questionnaires enable the evaluation of relevant
events. We previously developed a questionnaire to assess the quality of
life of patients with AF (AFQLQ version 1), which was reviewed in this
study, and new domains were added.ObjectiveTo demonstrate the reproducibility of the AFQLQ version 2 (AFQLQ v.2), which
included the domains of fatigue, illness perception and well-being.MethodsWe applied 160 questionnaires (AFQLQ v.2 and SF-36) to 40 patients, at
baseline and 15 days after, to measure inter- and intraobserver
reproducibility. The analysis of quality of life stability was determined by
test-retest, applying the Bartko intraclass correlation coefficient (ICC).
Internal consistency was assessed by Cronbach's alpha test.ResultsThe total score of the test-retest (n = 40) had an ICC of 0.98 in the AFQLQ
v.2, and of 0.94 in the SF36. In assessing the intra- and interobserver
reproducibility of the AFQLQ v.2, the ICC reliability was 0.98 and 0.97,
respectively. The internal consistency had a Cronbach's alpha coefficient of
0.82, compatible with good agreement of the AFQLQ v.2.ConclusionThe AFQLQ v.2 performed better than its previous version. Similarly, the
domains added contributed to make it more comprehensive and robust to assess
the quality of life of patients with AF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.